NT5C3B

Across TCGA pan-cancer cohorts, NT5C3B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NT5C3B data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NT5C3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NT5C3B expression acts as an unfavorable survival marker.

ACC and LUSC are the cancer types where NT5C3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUSC	OS	Median	All	0.031	0.776	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

NT5C3B–ACC (DFS)

Open the ACC breakdown →